Showing 1 – 20 of 2018
Relevance | Newest | Oldest |
  • JAMA March 7, 2017

    Figure 2: Association of Damaging Lipoprotein Lipase Gene (LPL) Mutations With Coronary Artery Disease (CAD) Among 46 891 Individuals in 11 Studies

    In each study, the relationship of rare damaging mutations in LPL with risk of CAD was determined. P values for association tests and confidence intervals were determined using exact methods. A meta-analysis across studies was performed using Cochran-Mantel-Haenszel statistics for stratified 2-by-2 tables. This method combines score statistics and is particularly useful when some observed odds ratios are 0. An odds ratio in the Jackson Heart Study (JHS) cohort was not available (NA) owing to absence of identified carriers of a damaging LPL mutation. ATVB indicates Atherosclerosis, Thrombosis, and Vascular Biology Italian Study; DiscovEHR, DiscovEHR project of the Regeneron Genetics Center and Geisinger Health System; ESP-EOMI, Exome Sequencing Project Early-Onset Myocardial Infarction study; Leicester, Leicester Myocardial Infarction study; North German, North German Myocardial Infarction study; OHS, Ottawa Heart Study; PROCARDIS, Precocious Coronary Artery Disease study; PROMIS, Pakistan Risk of Myocardial Infarction Study; REGICOR, Registre Gironí del COR (Gerona Heart Registry) study; South German, South German Myocardial Infarction study; and dashed line, overall meta-analysis effect estimate.
  • JAMA September 8, 2015

    Figure: Advanced Multimodal Imaging in a Case of a 56-Year-Old Left-Handed Woman With Medically Refractory Epilepsy

    A, Magnetoencephalography identified a few possible abnormal discharges in the left temporal lobe, shown here as fused images with high-resolution T1-weighted anatomical magnetic resonance (MR) images. B, Metabolic imaging with simultaneous 18F-fluorodeoxyglucose–positron emission tomography/magnetic resonance imaging (18FDG PET/MRI) demonstrated hypometabolism in the left posterior medial temporal lobe. Arrowheads indicate decreased glucose uptake in the left posterior medial temporal lobe. C, Gradient echo MR image obtained at 7 T demonstrated extensive blood products abutting the left hippocampal tail along with a possible large draining vein. D, MR angiography performed at 7 T showed no abnormal vasculature in the left mesial temporal lobe. E, Task-based fMRI for presurgical planning showed right hemisphere activation corresponding to language eloquent cortex. F, Functional connectivity analysis with resting-state fMRI showed decreased connectivity throughout the default mode network in the left cerebral hemisphere. Surgical resection of the lesion in the left mesial temporal lobe demonstrated a thrombosed arteriovenous malformation.
  • Association of NSAID Use With Risk of Bleeding and Cardiovascular Events in Patients Receiving Antithrombotic Therapy After Myocardial Infarction

    Abstract Full Text
    free access
    JAMA. 2015; 313(8):805-814. doi: 10.1001/jama.2015.0809

    This analysis of data from Danish administrative registries reports that among patients receiving antithrombotic therapy after myocardial infarction, use of nonsteroidal anti-inflammatory drugs was associated with increased risk of bleeding and thrombotic events.

  • FDA: Thrombosis Risk With Immune Globulin Products

    Abstract Full Text
    JAMA. 2013; 310(3):247-247. doi: 10.1001/jama.2013.15267
  • JAMA July 3, 2013

    Figure 2: Kaplan-Meier Analysis of Major Adverse Cardiovascular Events in the Full Study Sample and in Participants With BNP ≥50 pg/mL

    BNP indicates brain-type natriuretic peptide. Major adverse cardiovascular events included arrhythmia, transient ischemic attack, stroke, myocardial infarction, peripheral or pulmonary thrombosis/embolus, or heart failure. In the full sample, 51 (7.3%) of 697 patients were admitted for major adverse cardiovascular events in the intervention group and 71 (10.5%) of 677 were admitted in the control group. In participants with BNP ≥50 pg/mL, 35 (13.3%) of 263 were admitted for major adverse cardiovascular events in the intervention group and 45 (19.1%) of 235 were admitted in the control group.
  • Association Between Changes in Air Pollution Levels During the Beijing Olympics and Biomarkers of Inflammation and Thrombosis in Healthy Young Adults

    Abstract Full Text
    free access
    JAMA. 2012; 307(19):2068-2078. doi: 10.1001/jama.2012.3488
    Taking advantage of air pollution restrictions for the 2008 Olympics, Rich and colleagues compared blood serum levels in 125 medical students living in Beijing before, during, and after the games to determine whether cardiovascular disease biomarkers respond to variations in air pollution. In an editorial, Dominici and Mittleman discuss reconciling economic growth with environmental protections.
  • JAMA May 2, 2012

    Figure 3: Kaplan-Meier Estimates of Time to First Loss of Native Graft Patency, Thrombosis, Intervention, and Cardiovascular Event

    Median time to primary unassisted patency was 354 days in the fish oil group and 176 days in the placebo group. Intervention indicates radiological or surgical intervention to maintain graft patency.
  • Effect of Fish Oil Supplementation on Graft Patency and Cardiovascular Events Among Patients With New Synthetic Arteriovenous Hemodialysis Grafts: A Randomized Controlled Trial

    Abstract Full Text
    free access
    JAMA. 2012; 307(17):1809-1816. doi: 10.1001/jama.2012.3473
    To determine the effect of fish oil on synthetic arteriovenous hemodialysis graft patency and cardiovascular events, Lok and coauthors assigned 201 patients with end-stage renal disease to receive fish oil or matching placebo after graft creation. In a related Editorial, Dixon discusses increasing the use of hemodialysis grafts accompanied by administration of fish oil to prolong graft patency.
  • JAMA May 2, 2012

    Figure 2: Frequency of Arteriovenous Graft Events

    Primary events indicates thrombosis and radiological or surgical intervention to maintain graft patency. Interventions indicates radiological or surgical interventions to maintain graft patency. Error bars indicate 95%CIs.
  • Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis

    Abstract Full Text
    free access
    JAMA. 2011; 306(16):1765-1774. doi: 10.1001/jama.2011.1529
  • Scientists Report Progress on Engineered Blood Vessels

    Abstract Full Text
    JAMA. 2011; 305(12):1187-1187. doi: 10.1001/jama.2011.330
  • Benefits and Risks of Drug Treatments: How to Combine the Best Evidence on Benefits With the Best Data About Adverse Effects

    Abstract Full Text
    JAMA. 2008; 300(20):2417-2419. doi: 10.1001/jama.2008.723
  • JAMA August 27, 2008

    Figure: New Guidelines Issued for Prevention and Management of Thrombosis

    Updated guidelines for preventing and treating thrombosis give more explicit directions for managing certain patient populations on long-term antithrombotic therapy.
  • New Guidelines Issued for Prevention and Management of Thrombosis

    Abstract Full Text
    JAMA. 2008; 300(8):890-890. doi: 10.1001/jama.300.8.890
  • Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis: A Randomized Controlled Trial

    Abstract Full Text
    free access
    JAMA. 2008; 299(18):2164-2171. doi: 10.1001/jama.299.18.2164
  • Thrombosis Risk

    Abstract Full Text
    JAMA. 2008; 299(7):755-755. doi: 10.1001/jama.299.7.755-c
  • JAMA May 16, 2007

    Figure: New Drug-Eluting Stents Under Study

    This bioabsorbable stent is one of a number of new stents that are being studied to determine if they can prevent restenosis while avoiding late-event thrombosis.
  • JAMA February 28, 2007

    Figure: Heart Groups Issue Advisories for Reducing Drug-Eluting Stent Risks

    Treating coronary vessel blockage (left) with a drug-eluting stent improves blood flow (right), but experts caution that prolonged therapy with antiplatelet agents is advised to prevent thrombosis.
  • JAMA October 18, 2006

    Figure 3: Schema of Potential Dose Responses and Time Courses for Altering Clinical Events of Physiologic Effects of Fish or Fish Oil Intake

    The relative strength of effect is estimated from effects of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) on each risk factor and on the corresponding impact on cardiovascular risk. For example, dose response for antiarrhythmic effects is initially steep with a subsequent plateau, and clinical benefits may occur within weeks, while dose response for triglyceride effects is more gradual and monotonic, and clinical benefits may require years of intake. At typical Western levels of intake (eg, <750 mg/d EPA + DHA), the physiologic effects most likely to account for clinical cardiovascular benefits include (1) modulation of myocardial sodium and calcium ion channels, reducing susceptibility to ischemia-induced arrhythmia; and (2) reduced left ventricular workload and improved myocardial efficiency as a result of reduced heart rate, lower systemic vascular resistance, and improved diastolic filling. At higher levels of intake seen with fish oil supplementation or in Japanese populations (>750 mg/d EPA + DHA), maximum antiarrythmic effects have been achieved and clinically relevant effects occur on levels of serum triglycerides and possibly, at very high doses, thrombosis. Potentially important effects on endothelial, autonomic, and inflammatory responses are not shown because dose responses and time courses of such effects on clinical risk are not well established. Effects are not necessarily exclusive: eg, antiarrythmic effects may be partly mediated by effects on blood pressure (BP) or heart rate.